Crossmark

A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

Crossref DOI link: https://doi.org/10.1186/s13071-018-2634-x

Published Online: 2018-02-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kansiime, Freddie

Adibaku, Seraphine

Wamboga, Charles

Idi, Franklin

Kato, Charles Drago

Yamuah, Lawrence

Vaillant, Michel

Kioy, Deborah

Olliaro, Piero

Matovu, Enock
Funding

Funding for this research was provided by:

UNICEF/UNDP/World Bank/WHO
More Information

Article History

Received: 20 March 2017

Accepted: 10 January 2018

First Online: 22 February 2018

Ethics approval and consent to participate

: This study was approved by the WHO Ethics Review Committee, the National Ethics Committee of the Uganda Ministry of Health and the Uganda National Council for Science and Technology. All participants gave written informed consent and an independent data safety and monitoring board reviewed the study regularly.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below